Roche talks up Phase 3 success rate as it unveils pipeline cuts
Where other European pharmas — notably Novartis, Novo and AstraZeneca — have suffered huge late-stage clinical failures this summer, Roche is feeling rather smug. CEO Thomas Schinecker said ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.